Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice

(2015) Ilie-Cosmin Stancu et al.   ACTA NEUROPATHOLOGICA

Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies

(2015) Heii Arai et al.   Current Alzheimer Research

Distinct Therapeutic Mechanisms of Tau Antibodies

(2015) Kristen E. Funk et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preclinical Development of Inactivated Rabies Virus–Based Polyvalent Vaccine Against Rabies and Filoviruses

(2015) Mallory Willet et al.   JOURNAL OF INFECTIOUS DISEASES

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

(2015) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Biomarkers for Alzheimer's disease: a controversial topic

(2015) Giovanni B Frisoni et al.   LANCET NEUROLOGY

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

(2015) Markus Mandler et al.   Molecular Neurodegeneration

Human secreted tau increases amyloid-beta production

(2015) Jessica Bright et al.   NEUROBIOLOGY OF AGING

Prion-like features of misfolded Aβ and tau aggregates

(2015) Rodrigo Morales et al.   VIRUS RESEARCH

Implications of glial nitric oxide in neurodegenerative diseases

(2015) Jose Enrique Yuste et al.   Frontiers in Cellular Neuroscience

Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice

(2015) Si Liu et al.   Scientific Reports

A combination Alzheimer’s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice

(2015) Latha Devi et al.   Molecular Brain

Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference

(2015) Masaki Takahashi et al.   Molecular Therapy-Nucleic Acids

Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease

(2015) Md Shahaduzzaman et al.   PLoS One

Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

(2015) Jin-A Mo et al.   PLoS One

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

(2015) Sethu Sankaranarayanan et al.   PLoS One

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Convergence of pathology in dementia with Lewy bodies and Alzheimer’s disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease

(2014) Ashley R. Winslow et al.   BRAIN

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

(2014) Ludovic Collin et al.   BRAIN

Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy

(2014) Hong Xu et al.   CURRENT GENE THERAPY

Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

(2014) Francesco Panza et al.   Expert Review of Neurotherapeutics

The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios

(2014) Heike J. Wobst et al.   FEBS LETTERS

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease

(2014) Bidisha Roy et al.   HUMAN MOLECULAR GENETICS

Antibody-Derived In Vivo Imaging of Tau Pathology

(2014) S. Krishnaswamy et al.   JOURNAL OF NEUROSCIENCE

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

(2014) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Interactions between Amyloid-β and Tau Fragments Promote Aberrant Aggregates: Implications for Amyloid Toxicity

(2014) Thanh D. Do et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Alpha-synuclein and tau: teammates in neurodegeneration?

(2014) Simon Moussaud et al.   Molecular Neurodegeneration

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

(2014) Brian Spencer et al.   MOLECULAR THERAPY

Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance

(2014) Jakob Domert et al.   NEUROBIOLOGY OF DISEASE

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

(2014) Veronica Lindström et al.   NEUROBIOLOGY OF DISEASE

Cross Dimerization of Amyloid-β and αSynuclein Proteins in Aqueous Environment: A Molecular Dynamics Simulations Study

(2014) Jaya C. Jose et al.   PLoS One

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

(2014) Lars Lannfelt et al.   Alzheimers Research & Therapy

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

(2014) Hien T. Tran et al.   Cell Reports

Immunotherapy for Alzheimer’s disease: past, present and future

(2014) Brian Spencer et al.   Frontiers in Aging Neuroscience

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes

(2014) Cristian A Lasagna-Reeves et al.   Acta Neuropathologica Communications

Inflammation in Alzheimer’s disease: insights from immunotherapy

(2013) Jonathan M. Schott et al.   BRAIN

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

(2013) Erin E. Congdon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

(2013) Jiaping Gu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial

(2013) H. Davtyan et al.   JOURNAL OF NEUROSCIENCE

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

(2013) Elvira Valera et al.   PHARMACOLOGY & THERAPEUTICS

Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity

(2013) Cristina d’Abramo et al.   PLoS One

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

(2013) Clara Theunis et al.   PLoS One

Structural and functional characterization of two alpha-synuclein strains

(2013) Luc Bousset et al.   Nature Communications

Frontotemporal Dementia: Implications for Understanding Alzheimer Disease

(2013) M. Goedert et al.   Cold Spring Harbor Perspectives in Medicine

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?

(2013) Troels Nielsen et al.   Genes

Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease

(2013) Adrianne S. Chesser et al.   Frontiers in Neurology

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Interaction of Tau Protein with Model Lipid Membranes Induces Tau Structural Compaction and Membrane Disruption

(2012) Emmalee M. Jones et al.   BIOCHEMISTRY

Hsp70 Alters Tau Function and Aggregation in an Isoform Specific Manner

(2012) Kellen Voss et al.   BIOCHEMISTRY

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

(2012) Nadege Zommer et al.   Current Alzheimer Research

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease

(2012) Cristian A. Lasagna-Reeves et al.   FASEB JOURNAL

Trans-cellular Propagation of Tau Aggregation by Fibrillar Species

(2012) Najla Kfoury et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease

(2012) Doris Lambracht-Washington et al.   JOURNAL OF NEUROIMMUNOLOGY

Antibody-Aided Clearance of Extracellular  -Synuclein Prevents Cell-to-Cell Aggregate Transmission

(2012) E.-J. Bae et al.   JOURNAL OF NEUROSCIENCE

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies

(2012) Shubhada N. Joshi et al.   mAbs

Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD

(2012) Brian Spencer et al.   MOLECULAR THERAPY

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

(2012) Doris Lambracht-Washington et al.   Translational Neuroscience

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases

(2011) Joshua A. Smith et al.   BRAIN RESEARCH BULLETIN

Tau-targeted treatment strategies in Alzheimer's disease

(2011) Jürgen Götz et al.   BRITISH JOURNAL OF PHARMACOLOGY

DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

(2011) Doris Lambracht-Washington et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies

(2011) C. A. Lasagna-Reeves et al.   Current Alzheimer Research

FTD and ALS: A Tale of Two Diseases

(2011) R. Ferrari et al.   Current Alzheimer Research

Pathways towards an effective immunotherapy for Parkinson’s disease

(2011) Jessica AL Hutter-Saunders et al.   Expert Review of Neurotherapeutics

Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds

(2011) Mario Caruana et al.   FEBS LETTERS

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases

(2011) David T. Hickman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

(2011) Sherry L. La Porte et al.   JOURNAL OF MOLECULAR BIOLOGY

Immunotherapy for Tauopathies

(2011) Jiaping Gu et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-  Immunotherapy

(2011) A. Wang et al.   JOURNAL OF NEUROSCIENCE

Induction of Intracellular Tau Aggregation Is Promoted by  -Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau

(2011) E. A. Waxman et al.   JOURNAL OF NEUROSCIENCE

Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo

(2011) Tomohiro Umeda et al.   JOURNAL OF NEUROSCIENCE RESEARCH

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

(2011) Tim Bartels et al.   NATURE

Vaccination for Parkinson's disease

(2011) A. Schneeberger et al.   PARKINSONISM & RELATED DISORDERS

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

(2011) Kiran Yanamandra et al.   PLoS One

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

(2011) Eliezer Masliah et al.   PLoS One

Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy

(2011) Nahuai Badiola et al.   PLoS One

Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells

(2011) Thomas Näsström et al.   PLoS One

In vivo demonstration that  -synuclein oligomers are toxic

(2011) B. Winner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity

(2010) Karin M. Danzer et al.   FASEB JOURNAL

Molecular mechanisms of neurodegeneration in Alzheimer's disease

(2010) L. Crews et al.   HUMAN MOLECULAR GENETICS

Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease

(2010) Ashley D. Reynolds et al.   JOURNAL OF IMMUNOLOGY

Induction of Protective Immunity by Vaccination With Wild-Type Apo Superoxide Dismutase 1 in Mutant SOD1 Transgenic Mice

(2010) Shigeko Takeuchi et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Synergistic Interactions between A , Tau, and  -Synuclein: Acceleration of Neuropathology and Cognitive Decline

(2010) L. K. Clinton et al.   JOURNAL OF NEUROSCIENCE

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Vaccination as a Therapeutic Approach to Alzheimer's Disease

(2010) Thomas Wisniewski et al.   MOUNT SINAI JOURNAL OF MEDICINE

Cell-to-cell transmission of non-prion protein aggregates

(2010) Seung-Jae Lee et al.   Nature Reviews Neurology

Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies

(2009) Tetsuaki Arai et al.   ACTA NEUROPATHOLOGICA

The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain

(2009) Dave Morgan   CNS & Neurological Disorders-Drug Targets

Tau oligomers and aggregation in Alzheimer’s disease

(2009) Marco A. Meraz-Ríos et al.   JOURNAL OF NEUROCHEMISTRY

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

Does neuroinflammation fan the flame in neurodegenerative diseases?

(2009) Tamy C Frank-Cannon et al.   Molecular Neurodegeneration

An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease

(2009) Anna Lord et al.   NEUROBIOLOGY OF DISEASE

Dissecting the potential molecular mechanisms underlying α-synuclein cell-to-cell transfer in Parkinson's disease

(2009) Elodie Angot et al.   PARKINSONISM & RELATED DISORDERS

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  -synuclein

(2009) P. Desplats et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated Species†

(2008) Daniel Sevlever et al.   BIOCHEMISTRY

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

(2008) Mirjam Kool et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases

(2008) Igor F. Tsigelny et al.   PLoS One

An scFv Intrabody against the Nonamyloid Component of α-Synuclein Reduces Intracellular Aggregation and Toxicity

(2007) Sandra M. Lynch et al.   JOURNAL OF MOLECULAR BIOLOGY